Menu
Back to Journals » Open Access Emergency Medicine » Volume 16
The Eruptive Fevers at Sixes and Sevens
Authors Petrella RJ
Received 30 December 2023
Accepted for publication 17 April 2024
Published 24 April 2024 Volume 2024:16 Pages 101—105
DOI https://doi.org/10.2147/OAEM.S448246
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Hans-Christoph Pape
Robert J Petrella1– 6
1Harvard Medical School, Boston, MA, USA; 2Department of Chemistry & Chemical Biology, Harvard University, Cambridge, MA, USA; 3Emergency Departments, CharterCARE Health Partners, Providence and North Providence, RI, USA; 4Emergency Department, Boston VA Medical Center, Boston, MA, USA; 5Emergency Departments, Steward Health Care Systems, Boston and Methuen, MA, USA; 6Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
Correspondence: Robert J Petrella, Email [email protected]
Abstract: Sixth Disease (roseola infantum) and its primary causative agent, HHV-6, share names that numerically concur. This article examines and answers the question of whether that correspondence is by design or coincidental by briefly reviewing the history and nomenclature of the HHV viruses and the classic febrile rashes of childhood while highlighting some clinical and microbiologic features of HHV-6 infection.
Keywords: HHV-6, HHV-7, human herpesviruses, roseola infantum, sixth disease, Kawasaki disease, viral taxonomy, nomenclature, emergency medicine, historical coincidence
Background
Human herpesvirus type 6 (HHV-6) is a large, enveloped, double-stranded DNA virus that infects leukocytes by binding the CD46 and CD134 receptors,1–4 inducing chemokine and cytokine release.5–7 Viral transmission is thought to occur primarily within families8,9 through saliva,8,10 and the majority of children in the US are infected by the age of two.9 It is estimated that HHV-6 infection accounts for about 10–20% of emergency department (ED) visits among infants and young toddlers with a febrile illness,11–13 and up to 40% of the subset of those patients who are admitted to the hospital. In addition to fever, common presenting signs and symptoms include rash, upper respiratory symptoms, severe neutropenia, cough, lymphadenopathy, vomiting, diarrhea, irritability, seizures, Koplik/Nagayama’s spots, otitis, and a bulging anterior fontanelle.6,9,11,12,14–17 The acute clinical course is usually self-limited,12 but in some cases there are complications such as recurrent seizures, status epilepticus,17 encephalitis,18–20 and rarely rhabdomyolysis21 or myocarditis.22
About 10–30% of presenting HHV-6-infected children will develop the classic pink roseola rash after rapid defervescence9,11,12 that we label exanthem subitum and that triggers the diagnosis of roseola infantum or Sixth Disease.23 In the ED, these cases sometimes raise the question of whether HHV-6 and Sixth Disease were named after one another. It sounds plausible enough, if not likely. At least one popular medical website recently said that Sixth Disease is so named “because the human herpesvirus (HHV) type 6 most often causes the illness”.
History of Discovery and Nomenclature
The question then turns to whether the disease was named after the virus, or vice versa, or else whether the paired sixes were, in fact, just a historical accident. As most pediatricians know, Sixth Disease derives its name from its sixth position on the list of “eruptive fevers”—ie, febrile rashes—of childhood that clinicians had compiled24–26 in the early 1900’s based on the order in which the illnesses were first clinically described. The first five were measles, scarlet fever, rubella, a somewhat mysterious “Fourth Disease”,24 (identified by some as staphylococcal scalded skin syndrome27,28) and erythema infectiosum, a.k.a. Fifth Disease.29,30 The term “Sixth Disease” dates to at least as far back as the 1930’s.29,31–34 The HHV-6 virus, on the other hand, was not discovered until five decades later, in 1986, by a group of researchers at NIH35 headed by the virologist Robert C. Gallo, who also proved that HIV was the causative pathogen in AIDS.36,37 The clinical entity was, therefore, named well before the pathogen.
The Gallo group initially named the virus the human B-lymphotropic virus (HBLV), because it was shown to target and morphologically convert human B-cells, but the next year38 they proposed renaming it HHV-6. The proposed name change again raises the question of whether it related to the virus’s role in Sixth Disease. And, again, this may sound plausible, except that the cause of Sixth Disease was unknown in 1987. The NIH group recommended the change because they had learned by then that the virus targeted T-cells as well as B-cells. Since it was the sixth human herpesvirus to be isolated, after herpes simplex viruses 1 and 2, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus, (ie, HHV-1 through HHV-5, respectively),39 the new virus was named40 HHV-6, in compliance with the nomenclature guidelines put forward by the International Committee for Taxonomy of Viruses (ICTV).41,42
It was not until the following year, 1988, that the virus was shown to be the causative agent of Sixth Disease by researchers in Osaka.43 Dr. Gallo was kind enough to confirm through a personal communication that the proposed HHV-6 designation had nothing to do with roseola or Sixth Disease. Thus, the virus and the disease it causes were named independently. It is just an odd historical coincidence that they both happened to be sixth on their respective lists when they were. (The error on the medical website has subsequently been corrected.)
Later Developments
Since the 1980’s, the list of identified human herpesviruses has grown. There are currently eight of them, including HHV-7, and the Kaposi’s Sarcoma herpesvirus,44 a.k.a. HHV-8. In addition, the two main variants of HHV-6 have been named A and B.45,46 The variant thought to cause the majority of HHV-6 clinical disease in infants and toddlers in the U.S.47 and Japan,48 including Sixth Disease, was called HHV-6B, although febrile rashes and encephalitis have also been described with infantile HHV-6A infection in some other parts of the world,18,20,49,50 and the two viruses share ~90% sequence identity.51 In addition, HHV-6, like most other herpesviruses, has been found to cause latent infection52 that can manifest later in life.53–56 Unlike most other herpesviruses, however, both HHV-6 variants demonstrate the capacity to integrate directly into the host genome57 and transmit via germline58,59 from parent to offspring. This vertical transmission occurs in about 1% of the population60–62 and is called inherited chromosomally integrated HHV-6 (iciHHV-6). Mother-to-child transmission of either variant has also been found to sometimes occur transplacentally.63
As for the century-old numbered list of eruptive fevers of childhood, some have, over the decades, envisioned Kawasaki syndrome to be the Seventh Disease,64–67 and while HHV-7 is not (yet?) believed to be its causative agent, more recent studies have indicated that approximately 30% of Kawasaki patients have elevated blood levels of the virus’s DNA in the acute phase of the illness.68,69 This may arise from reactivation of prior infection rather than acute infection, but in either case it represents another historical coincidence.
While it is clear that the numerical agreement was unintended in both Sixth Disease/HHV-6 and Seventh Disease/HHV-7, the occurrence of two such coincidences back-to-back suggests a real effect at work. In particular, the earlier a disease is discovered or described, the earlier its pathogenesis is likely to be explored,70 and, similarly, the earlier a novel potential pathogen is identified, the earlier the search for a possible associated disease can begin.71,72 Either case may result in temporal cross-correlation.73 Hence, all else being equal, a pathogen and its associated disease may have a higher-than-random chance of appearing at the same ordinal position on their discovery lists.
Conclusion
The numerical correspondence between the names of Sixth Disease and its primary causative agent, HHV-6, arose by historical coincidence rather than by design. Both the disease and virus are part of nomenclature systems that add category members in the order of their date of discovery, and both happened to be the sixth members added to their respective categories. However, since the order in which diseases are discovered may correlate to some degree with the order in which they are studied and their pathogens identified, it is possible that the concurrence is not due entirely to chance.
Acknowledgments
The author thanks Victor Ovchinnikov, Yoshitatsu Sei, Raymond T. Chung, and the Open Access Emergency Medicine reviewers for helpful comments on the manuscript and Robert C. Gallo for his assistance. He thanks Harvard Medical School, Martin Karplus and the Department of Chemistry and Chemical Biology at Harvard and the Boston VA Medical Center for support of this work.
Disclosure
The author reports no conflicts of interest in this work.
References
1. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell. 1999;99(7):817–827. doi:10.1016/S0092-8674(00)81678-5
2. Johnstone RW, Loveland BE, McKenzie IF. Identification and quantification of complement regulator CD46 on normal human tissues. Immunology. 1993;79(3):341–347.
3. Tang H, Serada S, Kawabata A, et al. CD134 is a cellular receptor specific for human herpesvirus-6B entry. Proc Natl Acad Sci U S A. 2013;110(22):9096–9099. doi:10.1073/pnas.1305187110
4. Mori Y, Yang X, Akkapaiboon P, Okuno T, Yamanishi K. Human herpesvirus 6 variant A glycoprotein H-glycoprotein L-glycoprotein Q complex associates with human CD46. J Virol. 2003;77(8):4992–4999. doi:10.1128/JVI.77.8.4992-4999.2003
5. Wang FZ, Pellett, PE. HHV-6A, 6B, and 7: immunobiology and host response. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007.
6. Miura H, Kawamura Y, Ozeki E, Ihira M, Ohashi M, Yoshikawa T. Pathogenesis of Severe Neutropenia in Patients With Primary Human Herpesvirus 6B Infection. Pediatr Infect Dis J. 2015;34(9):1003–1007. doi:10.1097/INF.0000000000000777
7. Yoshikawa T, Kato Y, Ihira M, et al. Kinetics of cytokine and chemokine responses in patients with primary human herpesvirus 6 infection. J Clin Virol. 2011;50(1):65–68. doi:10.1016/j.jcv.2010.09.017
8. Rhoads MP, Magaret AS, Zerr DM. Family saliva sharing behaviors and age of human herpesvirus-6B infection. J Infect. 2007;54(6):623–626. doi:10.1016/j.jinf.2006.11.012
9. Zerr DM, Meier AS, Selke SS, et al. A Population-Based Study of Primary Human Herpesvirus 6 Infection. N Engl J Med. 2005;352(8):768–776. doi:10.1056/NEJMoa042207
10. Levy JA, Ferro F, Greenspan D, Lennette ET. Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet. 1990;335(8697):1047–1050. doi:10.1016/0140-6736(90)92628-U
11. Pruksananonda P, Hall CB, Insel RA, et al. Primary Human Herpesvirus 6 Infection in Young Children. N Engl J Med. 1992;326(22):1445–1450. doi:10.1056/NEJM199205283262201
12. Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med. 1994;331(7):432–438. doi:10.1056/NEJM199408183310703
13. Colvin JM, Muenzer JT, Jaffe DM, et al. Detection of Viruses in Young Children With Fever Without an Apparent Source. Pediatrics. 2012;130(6):e1455–e1462. doi:10.1542/peds.2012-1391
14. Vianna RA, de Oliveira SA, Camacho LAB, et al. Role of Human Herpesvirus 6 Infection in Young Brazilian Children With Rash Illnesses. Pediatr Infect Dis J. 2008;27(6):533–537. doi:10.1097/INF.0b013e3181673c50
15. Caserta MT, Hall CB, Schnabel K, Long CE, D’Heron N. Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children. J Pediatr. 1998;133(3):386–389. doi:10.1016/S0022-3476(98)70275-6
16. Asano Y, Yoshikawa T, Suga S, et al. Clinical Features of Infants With Primary Human Herpesvirus 6 Infection (Exanthem Subitum, Roseola Infantum). Pediatrics. 1994;93(1):104–108. doi:10.1542/peds.93.1.104
17. Mohammadpour Touserkani F, Gaínza-Lein M, Jafarpour S, Brinegar K, Kapur K, Loddenkemper T. HHV-6 and seizure: a systematic review and meta-analysis. J Med Virol. 2017;89(1):161–169. doi:10.1002/jmv.24594
18. Virtanen JO, Herrgård E, Valmari P, et al. Confirmed primary HHV-6 infection in children with suspected encephalitis. Neuropediatrics. 2007;38(6):292–297. doi:10.1055/s-2008-1065357
19. Crawford JR, Kadom N, Santi MR, Mariani B, Lavenstein BL. Human herpesvirus 6 rhombencephalitis in immunocompetent children. J Child Neurol. 2007;22(11):1260–1268. doi:10.1177/0883073807307086
20. Lou J, Wu Y, Cai M, Wu X, Shang S. Subtype-specific, probe-based, real-time PCR for detection and typing of human herpesvirus-6 encephalitis from pediatric patients under the age of 2 years. Diagn Microbiol Infect Dis. 2011;70(2):223–229. doi:10.1016/j.diagmicrobio.2011.01.002
21. Fujino M, Ohashi M, Tanaka K, Kato T, Asano Y, Yoshikawa T. Rhabdomyolysis in an Infant With Primary Human Herpesvirus 6 Infection. Pediatr Infect Dis J. 2012;31(11):1202–1203. doi:10.1097/INF.0b013e318266b3c9
22. Yoshikawa T, Ihira M, Suzuki K, et al. Fatal acute myocarditis in an infant with human herpesvirus 6 infection. J Clin Pathol. 2001;54(10):792–795.
23. James U, Freier A. Roseola Infantum: an Outbreak in a Maternity Hospital. Arch Dis Child. 1949;24(117):54–58. doi:10.1136/adc.24.117.54
24. Dukes C. On the confusion of two different diseases under the name of rubella (Rose-rash). Lancet. 1900;156(4011): 89–95
25. Shapiro L. The Numbered Diseases: first Through Sixth. JAMA. 1965;194(6):680. doi:10.1001/jama.1965.03090190102038
26. Bialecki C, Feder HM Jr, Grant-Kels JM. The six classic childhood exanthems: a review and update. J Am Acad Dermatol. 1989;21(5 Pt 1):891–903. doi:10.1016/S0190-9622(89)70275-9
27. Morens DM, Katz AR. The “fourth disease” of childhood: reevaluation of a nonexistent disease. Am J Epidemiol. 1991;134(6):628–640. doi:10.1093/oxfordjournals.aje.a116135
28. Weisse ME. The fourth disease, 1900-2000. Lancet. 2001;357(9252):299–301. doi:10.1016/S0140-6736(00)03623-0
29. Rector JM. Erythema infectiosum. J Pediatr. 1939;15(4):540–545. doi:10.1016/S0022-3476(39)80010-5
30. Greenwald P, Bashe, WJ. An Epidemic of Erythema Infectiosum. Amer J Dis Child 1964;107(1):30–34. doi:10.1001/archpedi.1964.02080060032005
31. Shaw HLK. Erythema Infectiosum. In: Nelson Loose-Leaf Living Medicine. New York: Thomas Nelson & Sons; 1932:28.
32. University of Michigan Medical School. Eighty-Second Session Announcement, 1931-1932. Vol. 32. Ann Arbor, MI: The University of Michigan Press; 1931:80.
33. Kennedy F, Cecil RL. A Textbook of Medicine.
34. Dreyfus JR. Three-day Fever of Young Children with terminal exanthem and granulocytopenia (Sixth Disease). Int Surveys Recent Adv Med. 1937;1:39.
35. Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science. 1986;234(4776):596–601. doi:10.1126/science.2876520
36. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984;224(4648):500–503. doi:10.1126/science.6200936
37. Vahlne A. A historical reflection on the discovery of human retroviruses. Retrovirology. 2009;6(1):40. doi:10.1186/1742-4690-6-40
38. Ablashi DV, Salahuddin SZ, Josephs SF, et al. HBLV (or HHV-6) in human cell lines. Nature. 1987;329(6136):207. doi:10.1038/329207a0
39. Roizman B, Carmichael LE, Deinhardt F, et al. Herpesviridae. Intervirology. 1981;16(4):201–217. doi:10.1159/000149269
40. Ablashi D, Agut H, Alvarez-Lafuente R, et al. Classification of HHV-6A and HHV-6B as distinct viruses. Arch. Virol. 2014;159(5):863–870. doi:10.1007/s00705-013-1902-5
41. Adams MJ, Lefkowitz EJ, King AM, et al. 50 years of the International Committee on Taxonomy of Viruses: progress and prospects. Arch Virol. 2017;162(5):1441–1446. doi:10.1007/s00705-016-3215-y
42. Louten J. Herpesviruses. In: Essential Human Virology. Elsevier Science; 2022.
43. Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988;1(8594):1065–1067. doi:10.1016/S0140-6736(88)91893-4
44. Chang Y, Cesarman E, Pessin MS, et al. Identification of Herpesvirus-Like DNA Sequences in AIDS-Associated Kaposi’s Sarcoma. Science. 1994;266(5192):1865–1869. doi:10.1126/science.7997879
45. Adams MJ, Carstens EB. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2012). Arch Virol. 2012;157(7):1411–1422. doi:10.1007/s00705-012-1299-6
46. Ablashi D, Agut H, Alvarez-Lafuente R, et al. Classification of HHV-6A and HHV-6B as distinct viruses. Arch. Virol. 2014;159(5):863–870 doi:10.1007/s00705-013-1902-5.
47. Dewhurst S, McIntyre K, Schnabel K, Hall CB. Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants. J Clin Microbiol. 1993;31(2):416–418. doi:10.1128/jcm.31.2.416-418.1993
48. Hattori F, Kawamura Y, Kozawa K, et al. Clinical Characteristics of Primary HHV-6B Infection in Children Visiting the Emergency Room. Pediatr Infect Dis J. 2019;38(10):e248–e253. doi:10.1097/INF.0000000000002379
49. Kasolo FC, Mpabalwani E, Gompels UA. Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi’s sarcoma in Africa. J Gen Virol. 1997;78(4):847–856. doi:10.1099/0022-1317-78-4-847
50. Bates M, Monze M, Bima H, et al. Predominant human herpesvirus 6 variant A infant infections in an HIV-1 endemic region of Sub-Saharan Africa. J Med Virol. 2009;81(5):779–789. doi:10.1002/jmv.21455
51. Forni D, Cagliani R, Clerici M, Pozzoli U, Sironi M. Evolutionary analysis of exogenous and integrated HHV-6A/HHV-6B populations. Virus Evolution. 2020;6(1):veaa035. doi:10.1093/ve/veaa035
52. Kondo K, Kondo T, Okuno T, Takahashi M, Yamanishi K. Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol. 1991;72(Pt 6):1401–1408. doi:10.1099/0022-1317-72-6-1401
53. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40(7):932–940. doi:10.1086/428060
54. Lareau CA, Yin Y, Maurer K, et al. Latent human herpesvirus 6 is reactivated in CAR T cells. Nature. 2023;623(7987):608–615. doi:10.1038/s41586-023-06704-2
55. Broccolo F, Drago F, Paolino S, et al. Reactivation of human herpesvirus 6 (HHV-6) infection in patients with connective tissue diseases. J Clin Virol. 2009;46(1):43–46. doi:10.1016/j.jcv.2009.05.010
56. Yoshikawa T, Fujita A, Yagami A, et al. Human herpesvirus 6 reactivation and inflammatory cytokine production in patients with drug-induced hypersensitivity syndrome. J Clin Virol. 2006;37(Suppl 1):S92–96. doi:10.1016/S1386-6532(06)70019-1
57. Luppi M, Marasca R, Barozzi P, et al. Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA. J Med Virol. 1993;40(1):44–52. doi:10.1002/jmv.1890400110
58. Daibata M, Taguchi T, Sawada T, Taguchi H, Miyoshi I. Chromosomal transmission of human herpesvirus 6 DNA in acute lymphoblastic leukaemia. Lancet. 1998;352(9127):543–544. doi:10.1016/S0140-6736(05)79251-5
59. Arbuckle JH, Medveczky MM, Luka J, et al. The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proc Natl Acad Sci U S A. 2010;107(12):5563–5568. doi:10.1073/pnas.0913586107
60. Leong HN, Tuke PW, Tedder RS, et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J med virol. 2007;79(1):45–51. doi:10.1002/jmv.20760
61. Gravel A, Dubuc I, Morissette G, Sedlak RH, Jerome KR, Flamand L. Inherited chromosomally integrated human herpesvirus 6 as a predisposing risk factor for the development of angina pectoris. Proc Natl Acad Sci U S A. 2015;112(26):8058–8063. doi:10.1073/pnas.1502741112
62. Hubacek P, Muzikova K, Hrdlickova A, et al. Prevalence of HHV-6 integrated chromosomally among children treated for acute lymphoblastic or myeloid leukemia in the Czech Republic. J med virol. 2009;81(2):258–263. doi:10.1002/jmv.21371
63. Hall CB, Caserta MT, Schnabel KC, et al. Transplacental congenital human herpesvirus 6 infection caused by maternal chromosomally integrated virus. J Infect Dis. 2010;201(4):505–507. doi:10.1086/650495
64. Powell KR. Filatow-Dukes’ disease. Epidermolytic toxin-producing staphylococci as the etiologic agent of the fourth childhood exanthem. Am J Dis Child. 1979;133(1):88–91. doi:10.1001/archpedi.1979.02130010094020
65. Patel M, Charlton R. First to seventh diseases: discarded diagnoses? Br Med J. 2015;351:h3525. doi:10.1136/bmj.h3525
66. Smith G. Slapped cheek is fifth disease: but what of the others? Br J Gen Pract. 2000;50(459):829.
67. Wikipedia. Exanthem. Available from: https://en.wikipedia.org/wiki/Exanthem.
68. Kawano Y, Kawada JI, Nagai N, Ito Y. Reactivation of human herpesviruses 6 and 7 in Kawasaki disease. Modern Rheumatol. 2019;29(4):651–655. doi:10.1080/14397595.2018.1510758
69. L’Huillier AG, Brito F, Wagner N, et al. Identification of Viral Signatures Using High-Throughput Sequencing on Blood of Patients With Kawasaki Disease. Frontiers in Pediatrics. 2019;7:524. doi:10.3389/fped.2019.00524
70. Meckawy R, Stuckler D, Mehta A, Al-Ahdal T, Doebbeling BN. Effectiveness of early warning systems in the detection of infectious diseases outbreaks: a systematic review. BMC Public Health. 2022;22(1):2216. doi:10.1186/s12889-022-14625-4
71. Tijsse-Klasen E, Koopmans MPG, Sprong H. Tick-Borne Pathogen – Reversed and Conventional Discovery of Disease. Front Public Health. 2014;2. doi:10.3389/fpubh.2014.00073
72. Branda JA, Rosenberg ES. Borrelia miyamotoi: a Lesson in Disease Discovery. Ann Internal Med. 2013;159(1):61–62. doi:10.7326/0003-4819-159-1-201307020-00009
73. Dean RT, Dunsmuir WTM. Dangers and uses of cross-correlation in analyzing time series in perception, performance, movement, and neuroscience: the importance of constructing transfer function autoregressive models. Behav Res. 2016;48(2):783–802. doi:10.3758/s13428-015-0611-2
© 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.